Intech Biopharm Corporation (TPEX: 6461)
Health Care · Pharmaceuticals · TW
NT$15.60
-2.50% today · -20.6% 1Y
Intech Biopharm Corporation (TPEX: 6461) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $87.37M and employs 96 people.
Over the last twelve months the share price has lost 20.6%, trading between 14.10 and 26.25.
Tweenvest scores Intech Biopharm Corporation across four factors: quality 25/100, value 43/100, growth 100/100. Its strongest factor is growth.
6461 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $87.37M
- Revenue (TTM)
- $1.53M
- P/E
- —
- EPS
- -2.84
- Dividend yield
- —
- Beta (5Y)
- 0.10
- 52-week high
- NT$26.25
- 52-week low
- NT$14.10
- Avg volume (3M)
- —
- Shares outstanding
- 178.35M
- Employees
- 96
- Next earnings
- —
About Intech Biopharm Corporation
Intech Biopharm Corporation is a pharmaceutical company dedicated to the global development and production of generic medications for respiratory conditions. Their portfolio includes innovative drug delivery systems, such as iLEF (inhaled low ethanol formulation), a proprietary metered dose inhaler platform specifically engineered for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Additionally, they offer a dry powder inhaler (DPI) technology, which utilizes blisters and capsules for precise dosage. These therapeutic solutions are marketed under various brand names, including SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011. Established in Taipei, Taiwan, in 2010, the company maintains its headquarters in the city.
- ISIN
- TW0006461007
- Founded
- 2010
- Listed since
- Jul 15, 2014
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.